Clinical Trial Detail

NCT ID NCT02763384
Title BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors Washington University School of Medicine
Indications

precursor T-lymphoblastic lymphoma/leukemia refractory

T-cell adult acute lymphocytic leukemia

Therapies

BKT140 + Nelarabine

Age Groups: adult

No variant requirements are available.